Albireo Pharma, Inc. (NASDAQ: ALBO)

Engel Law PLLC is investigating whether fair value to Albireo shareholders will result from the proposed sale of Albireo Pharma, Inc. (NASDAQ: ALBO) to Ipsen for $42.00 per share plus one contingent value right (CVR) of $10.00 per share.

The Firm’s investigation concerns:

(i) whether Albireo’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the $42.00 per share plus a contingent value right (CVR) of $10.00 per share merger consideration adequately compensates Albireo’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Join this Action

Albireo Pharma, Inc.

MM slash DD slash YYYY